When timely angioplasty is unavailable to older ST-segment elevation myocardial infarction (STEMI) patients, a modified pharmaco-invasive reperfusion strategy could be reasonable, according to the ...
Giving half-dose thrombolytic to ST-elevation myocardial infarction (STEMI) patients who are going to have a delay in receiving primary percutaneous coronary intervention (PCI), provided effective ...
Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...
BASEL, Switzerland—Multiple randomized trials presented last week at the European Stroke Organisation Conference (ESOC) 2024 have bolstered the case that tenecteplase (TNK) is an effective—if not ...
When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...
DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results